Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240709 | 0.89 | ALOX15 (0.37) | ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL12062893 | 0.84 | — | — | |
| SCHEMBL2570841 | 0.79 | ALOX15 (0.44) | ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL15966183 | 0.77 | DRD2 (0.31) | — | |
| SCHEMBL12162878 | 0.76 | — | — | |
| SCHEMBL245775 | 0.76 | ALOX15 (0.31) | ALOX15ALOX12 | |
| SCHEMBL2570060 | 0.75 | ALOX15 (0.44) | ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL2606319 | 0.75 | CYP19A1 (0.47) | ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL10042945 | 0.74 | ALOX12 (0.42) | ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL12052438 | 0.73 | ALOX12 (0.41) | ALOX15ALOX12KCNH2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-05-19 | — | — | US | disclosed |
| US-9198895-B2 | Chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150238458-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-08-27 | — | — | US | disclosed |
| US-8957109-B2 | Chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140161908-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8461361-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8163795-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120004296-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| US-8080675-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238458-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 3665/4885ALOX12 3724/4885SCN9A 4828/4885 |
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 3665/4885ALOX12 3724/4885SCN9A 4828/4885 |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 3665/4885ALOX12 3724/4885SCN9A 4828/4885 |
| US-20140161908-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 4133/4885ALOX12 4083/4885SCN9A 4849/4885 |
| US-20120004296-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 3665/4885ALOX12 3724/4885SCN9A 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.